Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 1
2007 3
2008 2
2009 17
2010 29
2011 15
2012 13
2013 12
2014 9
2015 8
2016 5
2017 5
2018 4
2019 6
2020 6
2021 9
2022 12
2023 16
2024 16
2025 31
2026 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Results by year

Filters applied: . Clear all
Page 1
Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group.
Şahin G, Tüzün EK, Güzel HG, Guliyev M, Dişli AK, Yazıcı M, Yıldız O, Güneş TK, Alkan S, Kahraman EG, Özel GS, İçli MC, Şahin E, Muğlu H, Acar C, Tunbekici S, Yüksel HÇ, Yücel H, Kahya BU, Kitaplı S, Büyükşimşek M, İpek ŞA, Dama PE, Usta EA, Yılmaz M, Aşık E, Özalp FR, Savsar MG, Kocaaslan E, Sim S, Ağaoğlu AB, Çamöz ES, Demir T, Uyar GC, Yıldırım A, Çınkır HY, Salim DK, Doğu GG, Alan Ö, Bayram E, Karaçin C, Güç ZG, Ekinci F, Eryılmaz MK, Semiz HS, Ünal OÜ, Göksu SS, Öztürk B, İnanç M, Uygun K, Hacıbekiroğlu İ, Erçolak V, Kara İO, Yazıcı O, Bilici A, Tanrıverdi Ö, Karaca B, Erman M, Gökmen E, Göker E, Yıldırım HÇ. Şahin G, et al. Among authors: bilici a. Int J Cancer. 2026 Feb 15;158(4):1067-1079. doi: 10.1002/ijc.70165. Epub 2025 Sep 19. Int J Cancer. 2026. PMID: 40968962
The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.
Muğlu H, Helvacı K, Köylü B, Yücel MH, Celayir ÖM, Demirci U, Uluç BO, Başaran G, Korkmaz T, Selçukbiricik F, Ölmez ÖF, Bilici A. Muğlu H, et al. Among authors: bilici a. Cancers (Basel). 2025 May 7;17(9):1592. doi: 10.3390/cancers17091592. Cancers (Basel). 2025. PMID: 40361516 Free PMC article.
Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study.
Mildanoglu MM, Kutlu Y, Bas O, Koylu B, Dae SA, Sakin A, Erdem D, Sendur MAN, Tasci ES, Dane F, Kaya AO, Aykan MB, Ergun Y, Biter S, Dizdar O, Disel U, Selcukbiricik F, Kose F, Olmez OF, Demir G, Yalcin S, Bilici A. Mildanoglu MM, et al. Among authors: bilici a. Sci Rep. 2025 Jul 13;15(1):25336. doi: 10.1038/s41598-025-09707-3. Sci Rep. 2025. PMID: 40653542 Free PMC article.
Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG).
Majidova N, Yaslıkaya S, Mıldanoglu MM, Coskun A, Ercan Uzundal D, Sahin TK, Akyildiz A, Akbas S, Camanlı U, Sahin E, Atacan H, Bayrakcı I, Sakalar T, Mordag Cicek C, Gunenc D, İlhan N, Unal OU, Alan O, Hamitoglu B, Ozen Engin E, Sever N, Guren AK, Unsal A, Araz M, Erdogan B, Aykan MB, Selcukbiricik F, Guven DC, Ozdemir N, Sahin AB, Bilici A, Kara IO, Yalcın S, Kostek O. Majidova N, et al. Among authors: bilici a. Turk J Gastroenterol. 2025 Apr 7;36(5):293-301. doi: 10.5152/tjg.2025.24784. Turk J Gastroenterol. 2025. PMID: 40241388 Free PMC article.
Prognostic Factors for Operated Gallbladder Cancer.
Oven Ustaalioglu BB, Bilici A, Seker M, Kefeli U, Aydin D, Celik S, Demir T, Erkol B. Oven Ustaalioglu BB, et al. Among authors: bilici a. J Gastrointest Cancer. 2019 Sep;50(3):451-457. doi: 10.1007/s12029-018-0099-y. J Gastrointest Cancer. 2019. PMID: 29637517
Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a.
Soran A, Göktepe B, Demirors B, Aytac O, Ozbas S, Dogan L, Can Trablus D, Al-Azhri J, Senol K, Zaveri S, Meas S, Demirci U, Karanlik H, Soyder A, Dag A, Bilici A, Dogan M, Sendur MAN, Koksal H, Gulcelik MA, Cabioglu N, Yeniay L, Utkan Z, Karadurmus N, Daglar G, Simsek T, Yildiz B, Uras C, Tukenmez M, Ozaslan C, Karaman N, Isik A, Sezgin E, Ozmen V, Lucci A. Soran A, et al. Among authors: bilici a. Curr Oncol. 2025 Oct 3;32(10):556. doi: 10.3390/curroncol32100556. Curr Oncol. 2025. PMID: 41149476 Free PMC article.
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.
Telli TA, Tatlı AM, Alan Ö, Keskin GY, Karadurmuş N, Karakaya S, Kaplan MA, Açıkgöz Ö, Bilici A, Mocan EE, Demirkazık A, Kahraman S, Şendur MA, Doğan M, Selam MT, Er Ö, Ünsal O, Yazıcı O, Özcan E, Kargı A, Gürbüz M, Selçukbiricik F, Şakalar T, Gürsoy P, Bilgin B, Selvi O, Karadağ İ, Eren OÖ, Bayram E, Sümbül AT, Keskin S, Öztürk A, Topçu S, Özen M, Kılıçkap S, Yumuk PF. Telli TA, et al. Among authors: bilici a. Clin Lung Cancer. 2025 Dec;26(8):e649-e659. doi: 10.1016/j.cllc.2025.07.015. Epub 2025 Jul 22. Clin Lung Cancer. 2025. PMID: 40813186
201 results